CCM
HQL

Coldstream Capital Management’s abrdn Life Sciences Investors HQL Stock Holding History

Coldstream Capital Management’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-39
Closed -$495 – 2093
2025
Q1 		$495 Buy
+39
New +$528 ﹤0.01% 3359

Other funds holding HQL

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Coldstream Capital Management's HQL Position: Q2 2025 in Review

Coldstream Capital Management sold out of abrdn Life Sciences Investors (HQL) in Q2 2025, closing a stake of 39 shares — an estimated $495 sold.

Coldstream Capital Management first reported a position in HQL in Q1 2025 and held it in 1 quarter. The position peaked at $495 in Q1 2025. 75 funds tracked by Wall St. Rank hold HQL as of Q2 2025.

  • Coldstream Capital Management reported no remaining abrdn Life Sciences Investors position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 39 abrdn Life Sciences Investors shares in Q2 2025, an estimated $495.
  • Coldstream Capital Management first reported a position in abrdn Life Sciences Investors in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's abrdn Life Sciences Investors position peaked at $495 in Q1 2025.
  • 75 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.